Predictive Factors of Lamivudine Treatment Success in a Hepatitis B Virus-Infected Pediatric Cohort: A 10-Year Study
BACKGROUND: Hepatitis B virus (HBV) infections are responsible for the development of chronic hepatitis in 400 million people worldwide. Currently, no consensus exists as to when treatment should be initiated for pediatric patients.
Saved in:
Main Authors: | Yasmine Yousef, Kathie Béland, Emmanuel Mas, Pascal Lapierre, Dorothée Bouron Dal Soglio, Fernando Alvarez |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2012-01-01
|
Series: | Canadian Journal of Gastroenterology |
Online Access: | http://dx.doi.org/10.1155/2012/928912 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Lamivudine for the Treatment of Membranous Glomerulopathy Secondary to Chronic Hepatitis B Infection
by: SI Gan, et al.
Published: (2005-01-01) -
Reassessing the Role for Lamivudine in Chronic Hepatitis B Infection: A Four-Year Cohort Analysis
by: Tahir Shaikh, et al.
Published: (2012-01-01) -
Spectrophotometric Determination of Lamivudine in Pure and Tablet Forms
by: A. Biksham Babu, et al.
Published: (2012-01-01) -
Regulatory T Cells in Autoimmune and Viral Chronic Hepatitis
by: Pascal Lapierre, et al.
Published: (2015-01-01) -
Hepatitis C Virus–Pediatric and Adult Perspectives in the Current Decade
by: Nanda Kerkar, et al.
Published: (2024-12-01)